Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a daily vitamin slow the hardening of heart arteries?

NCT ID NCT05500443

Disease control Sponsor: Odense University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 26, 2026 · Last updated Aug 27, 2026 · Updated 1 time

Summary

This trial tests whether taking vitamin K2 (with vitamin D) every day can slow the progression of calcium buildup in the coronary arteries—a key risk factor for heart attacks. It enrolls 400 men and women with severe coronary calcification, who are randomly assigned to receive the supplement or a placebo for two years. CT scans at the start, 12 months, and 24 months measure changes in calcium score. The goal is to see if this simple supplement can put the brakes on the calcification process.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Vitamin K2 (Menaquinone-7) with vitamin D
What this could lead to
If it works, this could point toward a simple daily supplement to slow the progression of coronary artery calcification, potentially reducing heart attack risk.
What could go wrong
This is an early-stage trial, and the results may not confirm the hoped-for benefit. The supplement is generally safe, but its effect on heart health is not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

400 people

The number who actually took part.

Started

Feb 2023

Finished

Jul 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Coronary artery calcium (CAC) score above 400 Exclusion Criteria: * History of myocardial infarction or coronary revascularization * History of venous thrombosis including pulmonary embolism * Coagulation disorders * Vitamin K antagonist use * Disorders of calcium and phosphate metabolism (as primary hyperparathyroidism) * Women of childbearing age (due to radiation issues) * A life-expectancy \< 5 years

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Coronary artery disease are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cardiovascular disorder coronary artery disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Coronary artery disease

Contacts and locations

Locations

  • Department of Cardiology

    Svendborg, Denmark

  • Department of Cardiology

    Vejle, Denmark

  • Department of Cardiology, Odense University Hospital

    Odense, Odense C, DK-5000, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.